Rhythms in Human Gastrointestinal Mucosa and Skin

Bjarnason, Georg A.; Jordan, Richard C.

doi:10.1081/cbi-120002595

Cited by 74 publications

(41 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These rhythms have also been uncovered in human bone marrow, skin, and oral and rectal mucosae (Smaaland et al 1991(Smaaland et al , 2002Bjarnason et al 2001;Bjarnason and Jordan 2002). The above 24-hour changes were first documented in laboratory rodents on light/dark (LD) synchronization and in humans on normal diurnal routine.…”

Section: Circadian Gating Of Cell Divisionmentioning

confidence: 98%

Cross-talks between Circadian Timing System and Cell Division Cycle Determine Cancer Biology and Therapeutics

Lévi

Filipski²,

Iurisci³

et al. 2007

Cold Spring Harbor Symposia on Quantitative Biology

View full text Add to dashboard Cite

Section: Circadian Gating Of Cell Divisionmentioning

confidence: 98%

Cross-talks between Circadian Timing System and Cell Division Cycle Determine Cancer Biology and Therapeutics

Lévi

Filipski²,

Iurisci³

et al. 2007

Cold Spring Harbor Symposia on Quantitative Biology

View full text Add to dashboard Cite

“…[39][40][41] The peak time for chronomodulated oxaliplatin at 4 PM corresponded to high reduced glutathione levels and high circulating proteins in blood. 40,42 In this article, we report our initial experience using chronomodulated HAI regimens in 29 consecutive patients with predominantly liver metastases from CRC who were referred to our institution after the failure of standard treatments.…”

mentioning

confidence: 99%

“…The peak time of chronomodulated irinotecan at 5 AM corresponded to low proportion of S-phase cells in healthy tissues and to high Bcl-2 messenger RNA expression in oral mucosa and, presumably, in other healthy tissues. 39 The peak time for the chronomodulated delivery of 5-FU at 4 AM corresponded to high intracellular activity of dehydropyrimidine dehydrogenase in healthy human blood cells and to low DNA synthesis in healthy target tissues,…”

mentioning

confidence: 99%

Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer

Bouchahda

Adam

Giacchetti

et al. 2009

Cancer

View full text Add to dashboard Cite

Original carbohydrate‐based acrylamides bearing one azide group in C‐2 or C‐6 position namely, 2‐[(2‐deoxy‐2‐azido‐α‐D‐mannopyranosyloxy)ethanamido]‐ethyl acrylamide (II) and 2‐[(6‐deoxy‐6‐azido‐α‐D‐glucopyranosyloxy)ethanamido]‐ethyl acrylamide (III), and their azide‐free analogue, 2‐[(α‐D‐glucopyranosyloxy)ethanamido]‐ethyl acrylamide (I), have been designed. Whereas the reversible addition fragmentation chain transfer (RAFT) process ensured the preparation of well‐defined glycopolymers from I, the polymerization of monomers II and III proved to be challenging at temperatures compatible with a thermally initiated radical process, due to the presumed concomitant 1,3‐cycloaddition reactions between the azide and the acrylamide moieties. In contrast to III, for which no polymer could be obtained under any conditions, performing the RAFT polymerization of II at 30 °C clearly favored the radical polymerization and conferred a controlled character to the process, affording well‐defined azide‐functionalized glycopolymers and block copolymers. The presence of numerous azide moieties was finally exploited to introduce carbohydrates onto the glycopolymer backbone through copper catalyzed azide‐alkyne cycloaddition. © 2011 Wiley Periodicals, Inc. J Polym Sci Part A: Polym Chem, 2011

show abstract

“…Several groups have reported daily or/and circadian rhythms in proliferation activity in these tissues. [58][59][60] Since cell sensitivity to anticancer agents is known to depend upon cell cycle stage, these observations provide a possible explanation for the time-of-day variations in drug-induced toxicity. Indeed, daily variations in radiation-induced apoptosis in mouse small intestine have been reported as a major determinant of circadian control of radiation response.…”

Section: Molecular Determinants Of Sensitivity To Anticancer Drugsmentioning

confidence: 99%

Circadian Clock Genes as Modulators of Sensitivity to Genotoxic Stress

Antoch

Kondratov

2007

Encyclopedia of Stress

View full text Add to dashboard Cite

A broad variety of organisms display circadian rhythms (i.e., oscillations with 24-hr periodicities) in many aspects of their behavior, physiology and metabolism. These rhythms are under genetic control and are generated endogenously at the cellular level. In mammals, the core molecular mechanism of the oscillator consists of two transcriptional activators, CLOCK and BMAL1, and their transcriptional targets, CRYPTOCHROMES (CRYS) and PERIODS (PERS). The CRY and PER proteins function as negative regulators of CLOCK/BMAL1 activity, thus forming the major circadian autoregulatory feedback loop. It is believed that the circadian clock system regulates daily variations in output physiology and metabolism through periodic activation/repression of the set of clock-controlled genes that are involved in various metabolic pathways. Importantly, circadian-controlled pathways include those that determine in vivo responses to genotoxic stress. By using circadian mutant mice deficient in different components of the molecular clock system, we have established genetic models that correlate with the two opposite extremes of circadian cycle as reflected by the activity of the CLOCK/BMAL1 transactivation complex. Comparison of the in vivo responses of these mutants to the chemotherapeutic drug, cyclophosphamide (CY), has established a direct correlation between drug toxicity and the functional status of the CLOCK/ BMAL1 transcriptional complex. We have also demonstrated that CLOCK/BMAL1 modulates sensitivity to drug-induced toxicity by controlling B cell responses to active CY metabolites. These results suggest that the sensitivity of cells to genotoxic stress induced by anticancer therapy may be modulated by CLOCK/BMAL1 transcriptional activity. Further elucidation of the molecular mechanisms of circadian control as well as identification of specific pharmacological modulators of CLOCK/BMAL1 activity are likely to lead to the development of new anti-cancer treatment schedules with increased therapeutic index and reduced morbidity. KeywordsCircadian; CLOCK; BMAL1; transcription; anticancer therapy ANTICANCER THERAPY-A DOUBLE-EDGED SWORDTwo major types of anticancer therapy-chemotherapy and radiation-were introduced into the clinic several decades ago and have demonstrated significant success in treating a variety of tumors. However, both types of anticancer therapy are compromised by accompanying nonspecific damage to normal tissues that often results in debilitating side effects. Well-

show abstract

Rhythms in Human Gastrointestinal Mucosa and Skin

Cited by 74 publications

References 60 publications

Cross-talks between Circadian Timing System and Cell Division Cycle Determine Cancer Biology and Therapeutics

Cross-talks between Circadian Timing System and Cell Division Cycle Determine Cancer Biology and Therapeutics

Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer

Circadian Clock Genes as Modulators of Sensitivity to Genotoxic Stress

Contact Info

Product

Resources

About